Hamburg City Health Study - a German Cohort Study
Launched by UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF · Apr 28, 2019
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
The Hamburg City Health Study is a large research project that aims to learn more about various health conditions, such as heart disease, stroke, and cancer. Researchers are looking for factors that can help predict these diseases and understand how they affect people's lives over time. This study is open to residents of Hamburg who are between 45 and 74 years old and can speak German well enough to understand the study materials and participate in interviews.
Participants will be asked to provide their written consent to join the study and will then take part in different health assessments at a study center. This is a great opportunity to contribute to important health research that could benefit many people in the future. If you or someone you know meets the age and residency requirements and is interested in helping advance our understanding of chronic diseases, this study may be a good fit!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Inhabitant of the city of Hamburg at the time of inclusion into the study (Inclusion is time of written consent)
- • Age 45 to 74 years
- • Personally signed informed consent
- Exclusion Criteria:
- • Insufficient knowledge of the German language, in order to understand study documents and computer assisted interview without translation
- • Physical or psychological incapability to travel to the study center and to cooperate in the investigations
About Universitätsklinikum Hamburg Eppendorf
Universitätsklinikum Hamburg-Eppendorf (UKE) is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, UKE integrates state-of-the-art facilities with a multidisciplinary approach, fostering collaboration among top-tier researchers, clinicians, and healthcare professionals. The institution is dedicated to improving patient outcomes by conducting rigorous scientific investigations that address critical health challenges, ultimately contributing to the development of novel therapies and enhancing medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hamburg, , Germany
Patients applied
Trial Officials
Stefan Blankenberg, Professor
Principal Investigator
Universitäres Herzzentrum Hamburg
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials